MedTrace Logo

HFSRT With Concurrent TMZ for Large BMs

NCT03778541 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2019-07-23

No results posted yet for this study

Summary

A multi-center randomized phase III trial was conducted to investigate the feasibility and safety of adding temozolomide to hypofractionated stereotactic radiotherapy for large brain metastases.

Conditions

Interventions

DRUG

Temozolomide

75mg/m2/d concurrent with radiotherapy, taken for at least 20 days.

RADIATION

hypofractionated radiotherapy

the regular radiation dose prescription is 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Jianping Xiao, Dr · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-03
Primary Completion
2022-12-03
Completion
2022-12-03

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03778541 on ClinicalTrials.gov